{
  "docId": "019de074-0cc8-70d5-8924-3a1b552a09af",
  "docSlug": "77b0d3b8437e31981ed49d98afb5005f",
  "documentTitle": "OmniAb | Investor Conference Presentation Deck | 43 slides",
  "authorId": "omniab",
  "authorName": "OmniAb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 43,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "thesis_headline",
  "function": "establish_context",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-0cc8-70d5-8924-3a1b552a09af/8",
  "deckHref": "/decks/019de074-0cc8-70d5-8924-3a1b552a09af",
  "deckJsonHref": "/decks/019de074-0cc8-70d5-8924-3a1b552a09af.json",
  "deckAnchorHref": "/decks/019de074-0cc8-70d5-8924-3a1b552a09af#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.92,
        "x": 0.04,
        "y": 0.66
      },
      "kind": "list",
      "text": "We believe this approach increases the efficiency and probability of success of therapeutic antibody discovery and may help limit the attrition of antibody product candidates in the clinic",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "055bf75c-d062-482b-9864-6b152ffdc83a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.92,
        "x": 0.04,
        "y": 0.47
      },
      "kind": "list",
      "text": "The ability of the immune system in our engineered transgenic animals to create optimized antibodies for human therapeutics is what we call Biological Intelligence",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "66a41c66-1345-40f6-bbe1-4989d3fd1777",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.92,
        "x": 0.04,
        "y": 0.23
      },
      "kind": "list",
      "text": "We believe that antibodies generated in vivo are superior to ones from other sources because they are naturally optimized through an iterative process that preferentially selects for antibodies with excellent specificity and developability profiles",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b3e411be-f429-4138-a37c-4cd19eb4fb37",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.5,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "What is Biological Intelligence™?",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ad8174eb-f7ad-4465-a0fe-f48244f6b38b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Thesis archetype",
      "slug": "thesis-archetype",
      "agent": null,
      "layer": "slide",
      "matchId": "b8c98a36-19da-443e-86ec-2eed932668a7",
      "evidence": "We believe that antibodies generated in vivo are superior to ones from other sources because they are naturally optimized through an iterative process that preferentially selects for antibodies with excellen",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 16,
      "from": 7,
      "beatId": "3040f323-ee51-48d4-9506-f542b79a5e56",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 7-16 present OmniAb's platform and its capabilities.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 16,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "d28165e9-330b-4b4c-9bd6-8826c981bf1a",
      "evidence": "Slides 6-16 imply that not using OmniAb's platform may lead to lower success rates for antibody medicines.",
      "position": 0,
      "objective": "Highlight the consequences of not adopting OmniAb's technology",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}